NCT00039780View on ClinicalTrials.gov

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

PHASE3CompletedINTERVENTIONAL
Enrollment

764

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

October 31, 2006

Study Completion Date

September 30, 2014

Conditions
Breast NeoplasmsBreast DiseasesMetastases, Neoplasm
Interventions
DRUG

BNP7787

The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.

DRUG

Placebo

The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.

Sponsors
All Listed Sponsors
collaborator

Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019.

UNKNOWN

lead

BioNumerik Pharmaceuticals, Inc.

INDUSTRY

NCT00039780 - Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel | Biotech Hunter | Biotech Hunter